Approval · Notice of Compliance 23435 · 2020
REACTINE: Notice of Compliance 23435
Issued April 8, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23435
- Date
- April 8, 2020
- Company
- McNeil Consumer Healthcare, division of Johnson & Johnson Inc.Markham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Labelling Only
- Reason
- Create a separate Product Monograph for the prescription
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REACTINE | Not yet assigned | — |
Medicinal ingredients
- CETIRIZINE HYDROCHLORIDE 20 MG per TAB